fbpx

Year

2012
BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the appointment of Mr. Offer Nonhoff as Chief Financial Officer. Mr. Nonhoff replaces Mr. Fredrik Groth who is leaving the Company to pursue new challenges. Mr. Nonhoff comes to BONESUPPORT from Lumenis, a...
  BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, reported today that it received SEK 70M; $9.9M; euro 8M in cash within the second and final tranche of funding. This is part of a larger investment that was announced in June 2011 when the...
  Promising safety and efficacy interim clinical results after 6 months of treatment in peanut-allergic children using Viaskin® Peanut presented at the European Academy of Allergy and Clinical Immunology EAACI ARACHILD Study is currently still ongoing DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy,...
Patent will expand intellectual property protection for MYDICAR – a first in class drug under clinical evaluation for advanced heart failure Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it has received a Notice of Allowance from the European Patent Office (EPO) for...
  NBS System now available to US patients for both motor and speech mapping of the cortex Helsinki, Finland — Nexstim Oy, a medical device company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the NexSpeech® module for use with the Navigated Brain Stimulation (NBS) System. In presurgical planning for patients with...
Additional Presentations at ATC Will Provide Supporting Evidence of the Activity and Tolerability of LCP-Tacro in Kidney and Liver Transplant Patients   Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that a subgroup analysis of African-American stable kidney transplant patients enrolled in Study 3001, a Phase 3 non-inferiority study, suggests that these patients may be safely...
The appointment of Key Opinion Leader (KOL) in Allergy and Immunology is of strategic importance to DBV BAGNEAUX, France, May 31, 2012 – DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Pr. Hugh Sampson to its world-class Scientific Advisory Board....
Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients at moderate-to-high risk of suffering PONV. Vomiting and especially nausea remain a major problem...
Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that it contemplates restructuring the company’s operations in order to fully focus its resources on the completion of the development and subsequent commercialization of LCP-TacroT, Veloxis’ product candidate for the prevention of organ rejection. It is planned that a discontinuation of other pipeline activities will take place, including...
 MPM Capital and LSP Life Sciences Partners join existing Celladon investment syndicate – Total capital proceeds of recent investment round increased to $53 million San Diego, California, May 7, 2012/PRNewswire/ — Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced the receipt of additional capital proceeds...
1 2 3 4 5

News

Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge